China Listed Bio-pharmaceutical Companies Report, 2008
  • May/2009
  • Hard Copy
  • USD $1,500
  • Pages:98
  • Single User License
    (PDF Unprintable)       
  • USD $1,600
  • Code: HJ005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,700

This report firstly gives an overview of China bio-pharmaceutical industry, and then analyses sub-industries, import & exports status of the industry; finally it expounds the operations and revenue, project investment, main business structure, latest development and future trend of key 20 bio-pharmaceutical companies.

Sales revenue of bio-pharmaceutical industry in Jan-Nov 2008 raised 29.8% compared with the same period of 2007, up 7.6 points; Sales cost saw a 33.9% YoY rise; and gross profit margin grew 28.2% year-on-year, down 2.5 percentage points. The rate of period expense was 15.8%, down 1.2 points from the same period of 2007.

In 2008, China exported 1,632.14 tons of human & animal blood products, antiserum and vaccines, down 29.7% year on year; the export value totaled US$56.92 million, down 85.3%; the export price per unit was US$34.87/kg, US$16.96/kg lower than 2007.

In addition, the import volume of human & animal blood products, antiserum and vaccines amounted to 8,977.90 tons, up 2.87 times; the import value totaled US$558.16 million, up 44.3%; unit import price was US$62.17/kg, US$167.37/kg lower than 2007.

Taking Hualan Biological Engineering Inc. as an example:

Revenue and Net Profit of Hualan Biological Engineering Inc., 2003-2008

Revenue Structure By Product of Hualan Biological Engineering Inc., 2008

1.Overview of China Bio-pharmaceutical Industry, 2008
1.1 Industry Development
1.2 Market 
1.2.1 Overview
1.2.2 Sub-industries
1.2.3 Import & Export

2. Shenzhen CAU Technology Co., Ltd (000004)
2.1 Company Profile
2.2 Operations and Revenue
2.3 Investment
2.4 Main Business Structure
2.5 Latest Development and Future Trend

3.Shenzhen Neptunus Bioengineering Co., Ltd (000078)
3.1 Company Profile
3.2 Operations and Revenue
3.3 Investment
3.4 Main Business Structure
3.5 Latest Development and Future Trend

4.Sihuan Pharmaceutical Co., Ltd (000605)
4.1 Company Profile
4.2 Operations and Revenue
4.3 Investment
4.4 Main Business Structure
4.5 Latest Development and Future Trend

5.Changchun High & New Technology Industries (Group) Inc. (000661)
5.1 Company Profile
5.2 Operations and Revenue
5.3 Investment
5.4 Main Business Structure
5.5 Latest Development and Future Trend

6.Chengzhi Co., Ltd (000990)
6.1 Company Profile
6.2 Operations and Revenue
6.3 Investment
6.4 Main Business Structure
6.5 Latest Development and Future Trend

7. Hualan Biological Engineering Inc.(002007)
7.1 Company Profile
7.2 Operations and Revenue
7.3 Investment
7.4 Main Business Structure
7.5 Latest Development and Future Trend

8.Shanghai Kehua Bio-engineering Co., Ltd (002022)
8.1 Company Profile
8.2 Operations and Revenue
8.3 Investment
8.4 Main Business Structure
8.5 Latest Development and Future Trend

9.Da An Gene Co., Ltd (002030)
9.1 Company Profile
9.2 Operations and Revenue
9.3 Investment
9.4 Main Business Structure
9.5 Latest Development and Future Trend

10.Beijing SL Pharmaceutical Co., Ltd (002038)
10.1 Company Profile
10.2 Operations and Revenue
10.3 Investment
10.4 Main Business Structure
10.5 Latest Development and Future Trend

11.Shanghai RAAS Blood Products Co., Ltd (002252)
11.1 Company Profile
11.2 Operations and Revenue
11.3 Investment
11.4 Main Business Structure
11.5 Latest Development and Future Trend

12.Ginwa Enterprise (Group) Co., Ltd (600080)
12.1 Company Profile
12.2 Operations and Revenue
12.3 Investment
12.4 Main Business Structure
12.5 Latest Development and Future Trend

13.Beijing Tiantan Biological Products Co., Ltd (600161)
13. 1 Company Profile
13.2 Operations and Revenue
13.3 Investment
13.4 Main Business Structure
13.5 Latest Development and Future Trend

14.China Animal Husbandry Industry Co., Ltd (600195)
14.1 Company Profile
14.2 Operations and Revenue
14.3 Investment
14.4 Main Business Structure
14.5 Latest Development and Future Trend

15.Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196)
15.1 Company Profile
15.2 Operations and Revenue
15.3 Investment
15.4 Main Business Structure
15.5 Latest Development and Future Trend

16.Inner Mongolia Jinyu Group Co., Ltd (600201)
16.1 Company Profile
16.2 Operations and Revenue
16.3 Investment
16.4 Main Business Structure
16.5 Latest Development and Future Trend

17.Shanghai Jiao Da Onlly Co., Ltd (600530)
17.1 Company Profile
17.2 Operations and Revenue
17.3 Investment
17.4 Main Business Structure
17.5 Latest Development and Future Trend

18.Beihai Gofar Marine Biological Industry Co., Ltd (600538)
18.1 Company Profile
18.2 Operations and Revenue
18.3 Investment
18.4 Main Business Structure
18.5 Latest Development and Future Trend

19.Zhongyuan Union Stem Cell Bioengineering Co., Ltd (600645)
19.1 Company Profile
19.2 Operations and Revenue
19.3 Investment
19.4 Main Business Structure
19.5 Latest Development and Future Trend

20.Star Lake Bioscience Co., Inc (600866)
20.1 Company Profile
20.2 Operations and Revenue
20.3 Investment
20.4 Main Business Structure
20.5 Latest Development and Future Trend

21.Tonghua Dongbao Pharmaceutical Co., Ltd (600867)
21.1 Company Profile
21.2 Operations and Revenue
21.3 Main Business Structure
21.4 Latest Development and Future Trend
Growth of Quarterly Revenue of Bio-pharmaceutical Industry, 2005Q1-2009Q1
Growth of Quarterly Total Profit of Bio-pharmaceutical Industry, 2005Q1-2009Q1
YoY Growth Rate of Sales Revenue and Total profit of Bio-pharmaceutical Industry, Jan-Nov 2008
Gross Profit Margin and Pre-tax Margin of Bio-pharmaceutical Industry, Jan-Nov2008
Top Six Immune Vaccines In Terms of Planned Investment in China 
Market Share of MMR Triple Vaccine in China, 2007 Market Share of Influenza Vaccine in China, 2007
Market Share of Antineoplastics in China 
Market Share of Plant-based Antitumor Drugs in China 
Rank of China’s Docetaxel Producers
Import of China’s Human & Animal Blood Products, Antiserum and Vaccine, Jan-Dec 2008
Export of China’s Human & Animal Blood Products, Antiserum and Vaccine, Jan-Dec 2008
Revenue and Net Profit of Shenzhen CAU Technology Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shenzhen CAU Technology Co., Ltd, 2003-2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Product, 2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Sector, 2008
Revenue Structure of Shenzhen CAU Technology Co., Ltd by Region, 2008
Revenue and Net Profit of Shenzhen Neptunus Bioengineering Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shenzhen Neptunus Bioengineering Co., Ltd, 2003-2008
Revenue Structure of Shenzhen Neptunus Bioengineering Co., Ltd by Sector, 2008
Revenue and Net Profit of Sihuan Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Sihuan Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Sichuan Pharmaceutical Co., Ltd by Product, 1H 2008
Revenue and Net Profit of Changchun High & New Technology Industries (Group) Inc., 2003-2008
Total Asset and Monetary Capital Changchun High & New Technology Industries (Group) Inc., 2003-2008
Revenue Structure of Changchun High & New Technology Industries (Group) Inc. by Product, 2008
Indices of Main Business Revenue, Cost and Gross Profit Margin of Changchun High & New Technology Industries (Group) Inc., 2008
Operating Profit Proportion of Changchun High & New Technology Industries (Group) Inc., 2008
Revenue and Net Profit of Chengzhi Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Chengzhi Co., Ltd, 2003-2008
Revenue Structure of Chengzhi Co., Ltd by Sector, 2008
Revenue Structure of Chengzhi Co., Ltd by Business, 2007-2008
Quarterly Revenue and Growth Rate of Profit of Chengzhi Co., Ltd, 2008
Shareholding Structure of Hualan Biological Engineering Inc.
Revenue and Net Profit of Hualan Biological Engineering Inc., 2003-2008 Total Asset and Monetary Capital of Hualan Biological Engineering Inc., 2003-2008 Revenue Structure of Hualan Biological Engineering Inc. by Product, 2008
Issued Quantity Proportion of Influenza Vaccines in China, 2008
Issued Quantity of Influenza Vaccines in China, 2007-2008
Issued Quantity Proportion of Hepatitis B Vaccines in China, 2008
Issued Quantity Proportion of ACYW135 Vaccine of Hualan Biological Engineering Inc., 2008
Revenue and Net Profit of Shanghai Kehua Bio-engineering Co., Ltd 2003-2008
Total Asset and Monetary Capital of Shanghai Kehua Bio-engineering Co., Ltd, 2003-2008
Revenue Structure of Shanghai Kehua Bio-engineering Co., Ltd by Product, 2008
Sales Growth of Hepatitis Immune Products of Shanghai Kehua Bio-engineering Co., Ltd, 2005-2008
Net Profit Margin of Hepatitis Immune Products of Shanghai Kehua Bio-engineering Co., Ltd,  2005-2008
Apparatus Sales Ratio of Shanghai Kehua Bio-engineering Co. increased from 2005-2008 
Revenue and Net Profit of Da An Gene Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Da An Gene Co., Ltd, 2003-2008
Revenue Structure of Da An Gene Co., Ltd by Product, 2008
China In-Vitro Diagnostics Sub-industries, 2008 
Revenue and Net Profit of Beijing SL Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital Beijing SL Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Beijing SL Pharmaceutical Co., Ltd by Product, 2008
Quarterly Revenue and Net Profit of Beijing SL Pharmaceutical Co., Ltd, 2005-2008
Quarterly Profitability of Beijing SL Pharmaceutical Co., Ltd, 2005-2008 
Revenue and Net Profit of Shanghai RAAS Blood Products Co., Ltd, 2005-2008
Total Asset and Monetary Capital of Shanghai RAAS Blood Products Co., Ltd, 2005-2008
Revenue Structure of Shanghai RAAS Blood Products Co., Ltd by Product, 2008
Sales by Product of Shanghai RAAS Blood Products Co., Ltd, 2007-2008
Sales Gross Profit Margin of Shanghai RAAS Blood Products Co., Ltd, 2008
Revenue from HSA and Intravenous Gammaglobulin, 2005-2008
Changes of Plasma Circulation in China
Revenue and Net Profit of Ginwa Enterprise (Group) Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Ginwa Enterprise (Group) Co., Ltd, 2003-2008
Revenue Structure by Sector of Ginwa Enterprise (Group) Co., Ltd, 2008
Revenue and Net Profit of Beijing Tiantan Biological Products Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Beijing Tiantan Biological Products Co., Ltd, 2003-2008
Revenue Structure of Beijing Tiantan Biological Products Co., Ltd by Product, 2008
Sales of Vaccine & Blood Products of Beijing Tiantan Biological Products Co., Ltd, 2006-2008
Issued Quantity of MMR Triple Vaccines of Beijing Tiantan Biological Products Co., Ltd, 2008-2009Q1
Issued Quantity of  Hepatitis B Vaccines of Beijing Tiantan Biological Products Co., Ltd, 2008-2009Q1
Product Structure of Chengdu Rongsheng Pharmaceuticals Co., Ltd before It Was Purchased 
Issued Quantity of HAS in China, 2008 Issued Quantity of Intravenous Gammaglobulin in China, 2008
Revenue and Net Profit of China Animal Husbandry Industry Co., Ltd, 2003-2008
Total Asset and Monetary Capital of China Animal Husbandry Industry Co., Ltd, 2003-2008
Revenue Structure of China Animal Husbandry Industry Co., Ltd by Sector, 2008
Revenue Structure of China Animal Husbandry Industry Co., Ltd, 2004-2008
Main Operating Profit Structure of China Animal Husbandry Industry Co., Ltd, 2004-2008
Main Operating Profit Rate of China Animal Husbandry Industry Co. by Product, 2004-2008
Key Immune Solutions to Animal Epidemic Issued by China Ministry of Agriculture, 2009 
Revenue and Net Profit of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2003-2008
Revenue Structure of Shanghai Fosun Pharmaceutical (Group) Co., Ltd by Product, 2008
Quarterly Performance of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2007-2008
Main Business Revenue Proportion of Shanghai Fosun Pharmaceutical (Group) Co., 2008
Main Business Profit Proportion of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2008
Performances of Main Businesses Shanghai Fosun Pharmaceutical (Group) Co., Ltd, 2004-2008
Revenue and Net Profit of Inner Mongolia Jinyu Group Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Inner Mongolia Jinyu Group Co., Ltd, 2003-2008
Revenue Structure of Inner Mongolia Jinyu Group Co., Ltd by Product, 2008
Main Business Revenue Structure of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Main Business Profit Structure of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Revenue form Animal Vaccine and Main operating Profit Rate of Inner Mongolia Jinyu Group Co., Ltd, 2005-2008
Revenue and Net Profit of Shanghai Jiao Da Onlly Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Shanghai Jiao Da Onlly Co., Ltd, 2003-2008
Revenue Structure of Shanghai Jiao Da Onlly Co., Ltd by Sector, 2008
Revenue and Net Profit of Beihai Gofar Marine Biological Industry Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Beihai Gofar Marine Biological Industry Co., Ltd 2003-2008
Revenue Structure of Beihai Gofar Marine Biological Industry Co., Ltd by Sector, 2008
Revenue and Net Profit of Zhongyuan Union Stem Cell Bioengineering Co., Ltd 2003-2008
Total Asset and Monetary Capital of Zhongyuan Union Stem Cell Bioengineering Co., Ltd 2003-2008
Revenue Structure by Sector of Zhongyuan Union Stem Cell Bioengineering Co., Ltd, 2008
Revenue and Net Profit of Star Lake Bioscience Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Star Lake Bioscience Co., Ltd, 2003-2008
Revenue Structure of Star Lake Bioscience Co., Ltd by Product, 2008
Shareholding Structure of Tonghua Dongbao Pharmaceutical Co., Ltd.
Revenue and Net Profit of Tonghua Dongbao Pharmaceutical Co., Ltd, 2003-2008
Total Asset and Monetary Capital of Tonghua Dongbao Pharmaceutical Co., Ltd, 2003-2008
Revenue Structure of Tonghua Dongbao Pharmaceutical Co. by Product, 2008
Sales and Profitability Analysis by Products of Tonghua Dongbao Pharmaceutical Co., Ltd, 2007-2008
Revenue from Recombinant Human Insulin of Tonghua Dongbao Pharmaceutical Co., Ltd, 2005-2008
Revenue Proportion of Recombinant Human Insulin Tonghua Dongbao Pharmaceutical Co., Ltd, 2005-2008
Net Profit and Asset of Key Subsidiary Companies of Tonghua Dongbao Pharmaceutical Co., Ltd, 2004-2008

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号